Chen Wen-jun, Yuan Shao-fei, Zhu Lin-jia, Sun Xiao-nan, Zheng Weie
Department of Cancer Center, the Third Affiliated Hospital of Wenzhou Medical College, Wenzhou 325200, China.
J BUON. 2014 Jul-Sep;19(3):692-7.
This study aimed to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with three-dimensional conformal radiotherapy (3D-CRT) in the treatment for locally advanced unresectable hepatocellular carcinoma (HCC).
From March 2000 to March 2009 a total of 158 patients with unresectable HCC treated and followed at our hospital were divided into TACE group (N=80) and TACE combined with 3D-CRT group (N=78). The TACE group was treated 3-6 times. In the combination group, 2-3 TACE courses were administered and 3D-CRT was performed 2 weeks after the last TACE. Three months after the end of treatment, imaging and serum AFP were carried out to assess the treatment efficacy.
The response rates of TACE and the combination groups were 53.7% (43/80) and 71.8% (58/78) (p<0.05). The 1, 2, and 3-year survival rates of patients in the TACE and combination groups were 58.75, 36.25, 16.25%, and 78.48, 55.12 and 25.64% (p<0.05), respectively. Treatment compliance was good, with at least 2 TACE administrations for each case and at least 52 Gy for radiotherapy. In the TACE and the combination group, there were 2 and 3 cases with grade III/IV toxicity, respectively, without treatment-related death.
3D-CRT in combination with TACE significantly improve the therapeutic outcome in patients with locally advanced unresectable HCC, without creating severe toxicity.
本研究旨在探讨经动脉化疗栓塞术(TACE)联合三维适形放疗(3D-CRT)治疗局部晚期不可切除肝细胞癌(HCC)的疗效和安全性。
选取2000年3月至2009年3月在我院接受治疗并随访的158例不可切除HCC患者,分为TACE组(N = 80)和TACE联合3D-CRT组(N = 78)。TACE组治疗3 - 6次。联合组进行2 - 3个TACE疗程,在最后一次TACE后2周进行3D-CRT。治疗结束3个月后,进行影像学检查和血清甲胎蛋白检测以评估治疗效果。
TACE组和联合组的有效率分别为53.7%(43/80)和71.8%(58/78)(p<0.05)。TACE组和联合组患者的1年、2年和3年生存率分别为58.75%、36.25%、16.25%和78.48%、55.12%和25.64%(p<0.05)。治疗依从性良好,每组至少进行2次TACE治疗,放疗剂量至少为52 Gy。TACE组和联合组分别有2例和3例出现III/IV级毒性反应,无治疗相关死亡病例。
3D-CRT联合TACE可显著提高局部晚期不可切除HCC患者的治疗效果,且不产生严重毒性。